# EverCommerce Inc.: financial statements, quarterly

EVCM · Nasdaq · CIK 1853145 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/evcm.md) · [Financials](/companies/evcm/financials.md) · [Filings](/companies/evcm/filings.md) · [Insiders](/companies/evcm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/evcm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [175](/filings/0001853145-24-000054.md) | [28.9 d](/filings/0001853145-26-000010.md) | [138](/filings/0001853145-25-000017.md) | [141](/filings/0001853145-25-000037.md) | [140](/filings/0001853145-25-000047.md) | [144 d](/filings/0001853145-26-000010.md) | [142](/filings/0001853145-26-000021.md) | [148](/filings/0001853145-26-000029.md) | [147](/filings/0001853145-25-000047.md) | [151 d](/filings/0001853145-26-000010.md) | [147](/filings/0001853145-26-000021.md) | [152](/filings/0001853145-26-000029.md) |
| Research and development | $m | [19.3](/filings/0001853145-24-000054.md) | [15.8 d](/filings/0001853145-26-000010.md) | [19.3](/filings/0001853145-25-000017.md) | [19.2](/filings/0001853145-25-000037.md) | [19.1](/filings/0001853145-25-000047.md) | [18.5 d](/filings/0001853145-26-000010.md) | [20.0](/filings/0001853145-26-000021.md) | [19.5](/filings/0001853145-26-000029.md) | [19.4](/filings/0001853145-25-000047.md) | [20.2 d](/filings/0001853145-26-000010.md) | [21.2](/filings/0001853145-26-000021.md) | [21.4](/filings/0001853145-26-000029.md) |
| Operating income | $m | [6.3](/filings/0001853145-24-000054.md) | [(5.7) d](/filings/0001853145-26-000010.md) | [(4.3)](/filings/0001853145-25-000017.md) | [7.7](/filings/0001853145-25-000037.md) | [10.2](/filings/0001853145-25-000047.md) | [12.6 d](/filings/0001853145-26-000010.md) | [14.2](/filings/0001853145-26-000021.md) | [15.8](/filings/0001853145-26-000029.md) | [16.0](/filings/0001853145-25-000047.md) | [13.3 d](/filings/0001853145-26-000010.md) | [12.6](/filings/0001853145-26-000021.md) | [17.5](/filings/0001853145-26-000029.md) |
| Interest expense | $m | not reported | not reported | [10.7](/filings/0001853145-25-000017.md) | [10.7](/filings/0001853145-25-000037.md) | [10.7](/filings/0001853145-25-000047.md) | [9.8 d](/filings/0001853145-26-000010.md) | [8.8](/filings/0001853145-26-000021.md) | [9.0](/filings/0001853145-26-000029.md) | [8.6](/filings/0001853145-25-000047.md) | [8.4 d](/filings/0001853145-26-000010.md) | [8.2](/filings/0001853145-26-000021.md) | [8.2](/filings/0001853145-26-000029.md) |
| Income tax | $m | [0.2](/filings/0001853145-24-000054.md) | [2.9 d](/filings/0001853145-26-000010.md) | [5.9](/filings/0001853145-25-000017.md) | [0.7](/filings/0001853145-25-000037.md) | [0.9](/filings/0001853145-25-000047.md) | [(1.7) d](/filings/0001853145-26-000010.md) | [0.5](/filings/0001853145-26-000021.md) | [1.2](/filings/0001853145-26-000029.md) | [1.2](/filings/0001853145-25-000047.md) | [(0.0) d](/filings/0001853145-26-000010.md) | [0.6](/filings/0001853145-26-000021.md) | [1.5](/filings/0001853145-26-000029.md) |
| Net income | $m | [(0.6)](/filings/0001853145-24-000054.md) | [(23.3) d](/filings/0001853145-26-000010.md) | [(16.3)](/filings/0001853145-25-000047.md) | [(3.4)](/filings/0001853145-25-000047.md) | [(9.2)](/filings/0001853145-25-000047.md) | [(12.2) d](/filings/0001853145-26-000010.md) | [(7.7)](/filings/0001853145-26-000029.md) | [8.2](/filings/0001853145-26-000029.md) | [11.1](/filings/0001853145-25-000047.md) | [6.0 d](/filings/0001853145-26-000010.md) | [7.2](/filings/0001853145-26-000029.md) | [9.7](/filings/0001853145-26-000029.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001853145-24-000054.md) | not reported | [(0.09)](/filings/0001853145-25-000017.md) | [(0.02)](/filings/0001853145-25-000037.md) | [(0.05)](/filings/0001853145-25-000047.md) | not reported | [(0.04)](/filings/0001853145-26-000021.md) | [0.04](/filings/0001853145-26-000029.md) | [0.06](/filings/0001853145-25-000047.md) | not reported | [0.04](/filings/0001853145-26-000021.md) | [0.05](/filings/0001853145-26-000029.md) |
| Basic EPS | $ per share | [0.00](/filings/0001853145-24-000054.md) | not reported | [(0.09)](/filings/0001853145-25-000017.md) | [(0.02)](/filings/0001853145-25-000037.md) | [(0.05)](/filings/0001853145-25-000047.md) | not reported | [(0.04)](/filings/0001853145-26-000021.md) | [0.04](/filings/0001853145-26-000029.md) | [0.06](/filings/0001853145-25-000047.md) | not reported | [0.04](/filings/0001853145-26-000021.md) | [0.05](/filings/0001853145-26-000029.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [87.3](/filings/0001853145-23-000032.md) | [92.6](/filings/0001853145-25-000009.md) | [90.0](/filings/0001853145-24-000035.md) | [86.7](/filings/0001853145-24-000047.md) | [102](/filings/0001853145-24-000054.md) | [136](/filings/0001853145-26-000010.md) | [148](/filings/0001853145-25-000017.md) | [151](/filings/0001853145-25-000037.md) | [107](/filings/0001853145-25-000047.md) | [130](/filings/0001853145-26-000029.md) | [129](/filings/0001853145-26-000021.md) | [133](/filings/0001853145-26-000029.md) |
| Current assets | $m | [179](/filings/0001853145-23-000032.md) | [180](/filings/0001853145-25-000009.md) | [195](/filings/0001853145-24-000035.md) | [196](/filings/0001853145-24-000047.md) | [197](/filings/0001853145-24-000054.md) | [218](/filings/0001853145-26-000010.md) | [269](/filings/0001853145-25-000017.md) | [279](/filings/0001853145-25-000037.md) | [236](/filings/0001853145-25-000047.md) | [213](/filings/0001853145-26-000029.md) | [216](/filings/0001853145-26-000021.md) | [218](/filings/0001853145-26-000029.md) |
| Total assets | $m | [1,541](/filings/0001853145-23-000032.md) | [1,518](/filings/0001853145-25-000009.md) | [1,483](/filings/0001853145-24-000035.md) | [1,467](/filings/0001853145-24-000047.md) | [1,451](/filings/0001853145-24-000054.md) | [1,421](/filings/0001853145-26-000010.md) | [1,414](/filings/0001853145-25-000017.md) | [1,419](/filings/0001853145-25-000037.md) | [1,403](/filings/0001853145-25-000047.md) | [1,372](/filings/0001853145-26-000029.md) | [1,368](/filings/0001853145-26-000021.md) | [1,364](/filings/0001853145-26-000029.md) |
| Current liabilities | $m | [109](/filings/0001853145-23-000032.md) | [117](/filings/0001853145-25-000009.md) | [114](/filings/0001853145-24-000035.md) | [117](/filings/0001853145-24-000047.md) | [109](/filings/0001853145-24-000054.md) | [111](/filings/0001853145-26-000010.md) | [117](/filings/0001853145-25-000017.md) | [118](/filings/0001853145-25-000037.md) | [117](/filings/0001853145-25-000047.md) | [101](/filings/0001853145-26-000029.md) | [104](/filings/0001853145-26-000021.md) | [102](/filings/0001853145-26-000029.md) |
| Total liabilities | $m | [679](/filings/0001853145-23-000032.md) | [692](/filings/0001853145-25-000009.md) | [682](/filings/0001853145-24-000035.md) | [683](/filings/0001853145-24-000047.md) | [680](/filings/0001853145-24-000054.md) | [670](/filings/0001853145-26-000010.md) | [675](/filings/0001853145-25-000017.md) | [675](/filings/0001853145-25-000037.md) | [675](/filings/0001853145-25-000047.md) | [655](/filings/0001853145-26-000029.md) | [654](/filings/0001853145-26-000021.md) | [649](/filings/0001853145-26-000029.md) |
| Long-term debt | $m | [528](/filings/0001853145-23-000032.md) | [527](/filings/0001853145-25-000009.md) | [526](/filings/0001853145-24-000035.md) | [525](/filings/0001853145-24-000047.md) | [524](/filings/0001853145-24-000054.md) | [522](/filings/0001853145-26-000010.md) | [521](/filings/0001853145-25-000017.md) | [520](/filings/0001853145-25-000037.md) | [519](/filings/0001853145-25-000047.md) | [518](/filings/0001853145-26-000029.md) | [517](/filings/0001853145-26-000021.md) | [515](/filings/0001853145-26-000029.md) |
| Current portion of debt | $m | [5.5](/filings/0001853145-23-000032.md) | [5.5](/filings/0001853145-25-000009.md) | [5.5](/filings/0001853145-24-000035.md) | [5.5](/filings/0001853145-24-000047.md) | [5.5](/filings/0001853145-24-000054.md) | [5.5](/filings/0001853145-26-000010.md) | [5.5](/filings/0001853145-25-000017.md) | [5.5](/filings/0001853145-25-000037.md) | [5.5](/filings/0001853145-25-000047.md) | [5.5](/filings/0001853145-26-000029.md) | [5.5](/filings/0001853145-26-000021.md) | [5.5](/filings/0001853145-26-000029.md) |
| Shareholders' equity | $m | [862](/filings/0001853145-24-000054.md) | [826](/filings/0001853145-26-000010.md) | [801](/filings/0001853145-25-000047.md) | [784](/filings/0001853145-25-000047.md) | [771](/filings/0001853145-25-000047.md) | [751](/filings/0001853145-26-000029.md) | [740](/filings/0001853145-26-000029.md) | [744](/filings/0001853145-26-000029.md) | [729](/filings/0001853145-25-000047.md) | [717](/filings/0001853145-26-000029.md) | [714](/filings/0001853145-26-000029.md) | [715](/filings/0001853145-26-000029.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [27.4 d](/filings/0001853145-24-000054.md) | [36.0 d](/filings/0001853145-26-000010.md) | [13.3](/filings/0001853145-25-000017.md) | [23.9 d](/filings/0001853145-25-000037.md) | [27.5 d](/filings/0001853145-25-000047.md) | [48.4 d](/filings/0001853145-26-000010.md) | [30.7](/filings/0001853145-26-000021.md) | [27.0 d](/filings/0001853145-26-000029.md) | [32.5 d](/filings/0001853145-25-000047.md) | [21.3 d](/filings/0001853145-26-000010.md) | [24.6](/filings/0001853145-26-000021.md) | [28.5 d](/filings/0001853145-26-000029.md) |
| Capital expenditure | $m | [0.9 d](/filings/0001853145-24-000054.md) | [0.9 d](/filings/0001853145-26-000010.md) | [0.4](/filings/0001853145-25-000017.md) | [0.6 d](/filings/0001853145-25-000037.md) | [0.2 d](/filings/0001853145-25-000047.md) | [0.3 d](/filings/0001853145-26-000010.md) | [0.5](/filings/0001853145-26-000021.md) | [0.5 d](/filings/0001853145-26-000029.md) | [0.9 d](/filings/0001853145-25-000047.md) | [0.3 d](/filings/0001853145-26-000010.md) | [0.9](/filings/0001853145-26-000021.md) | [0.6 d](/filings/0001853145-26-000029.md) |
| Share repurchases | $m | [1.6 d](/filings/0001853145-24-000054.md) | [26.0 d](/filings/0001853145-26-000010.md) | [12.1](/filings/0001853145-25-000017.md) | [24.0 d](/filings/0001853145-25-000037.md) | [14.6 d](/filings/0001853145-25-000047.md) | [7.1 d](/filings/0001853145-26-000010.md) | [11.1](/filings/0001853145-26-000021.md) | [20.5 d](/filings/0001853145-26-000029.md) | [28.9 d](/filings/0001853145-25-000047.md) | [24.6 d](/filings/0001853145-26-000010.md) | [13.8](/filings/0001853145-26-000021.md) | [14.7 d](/filings/0001853145-26-000029.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [195](/filings/0001853145-23-000032.md) | [190](/filings/0001853145-24-000035.md) | [188](/filings/0001853145-24-000047.md) | [189](/filings/0001853145-24-000054.md) | [187](/filings/0001853145-25-000017.md) | [185](/filings/0001853145-25-000037.md) | [184](/filings/0001853145-25-000047.md) | [185](/filings/0001853145-26-000021.md) | [184](/filings/0001853145-26-000029.md) | [184](/filings/0001853145-25-000047.md) | [180](/filings/0001853145-26-000021.md) | [179](/filings/0001853145-26-000029.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 176,665,246 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001853145-26-000029.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.